The post-authorization study is called Spectrum and some 2,000 treatment episodes were reported by 53 hospitals in the European Union.
"This large European registry provides important data on the safety, efficacy and use of Brinavess in 1,778 patients in a real-world setting," said Kiran Bhirangi, Correvio's vice-president for Clinical Development and Medical Affairs. "In Spectrum, normal heart rhythm was restored in over 70% of patients at a median time of 11 minutes, HOIs (health outcomes of interest) were observed in 0.8% (17) of patients, and there were no deaths."
HOIs are defined as significant hypertension or irregular heartbeats.
Shares of Correvio hit a day's high of US$4.99 and were trading 6.6% up at US$4.725.
Atrial fibrillation is an irregular and often rapid heart rate that can increase your risk of stroke, heart failure and other heart-related complications.
Correvio is a specialty pharmaceutical company based in Vancouver.